Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
malaria
Biotech
GSK anti-TIM-3 antibody flunks ph. 3, as TIGIT fail costs $629M
GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test.
James Waldron
Jul 30, 2025 5:27am
FDA slaps hold on BioNTech's malaria vaccine trial
Mar 4, 2025 5:30pm
Malaria drug shows early potential as PCOS treatment
Jun 18, 2024 5:00am
Malaria drug identified by AI protects and builds bone in mice
Oct 18, 2023 8:00am
GSK identifies bacterium with malaria-fighting potential
Aug 7, 2023 3:10pm
mRNA malaria vaccines take the sting out of not just infection
Dec 1, 2022 12:56pm